These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 2533157)

  • 1. Luteinising hormone-releasing hormone analogues alone in the treatment of advanced disease.
    Debruyne F
    Horm Res; 1989; 32 Suppl 1():62-4; discussion 64-5. PubMed ID: 2533157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LHRH analogues in combination with an anti-androgen in the treatment of advanced disease.
    Denis L
    Horm Res; 1989; 32 Suppl 1():66-7; discussion 68. PubMed ID: 2533158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology of the luteinising hormone-releasing hormone (LHRH) analogue, Zoladex.
    Furr BJ
    Horm Res; 1989; 32 Suppl 1():86-92. PubMed ID: 2533160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orchidectomy or LHRH-analogue? Which do the patients prefer and what treatment would Norwegian urologists prefer if they had advanced cancer of the prostate?
    Samdal F; Vada K; Lundmo PI; Mjølnerød OK
    Scand J Urol Nephrol; 1991; 25(3):197-9. PubMed ID: 1835129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Failure of long term luteinising hormone releasing hormone treatment for prostatic cancer to suppress serum luteinising hormone and testosterone.
    Ahmed SR; Shalet SM; Grant J; Howell A; Blacklock NJ
    Br Med J (Clin Res Ed); 1984 Sep; 289(6448):831. PubMed ID: 6236870
    [No Abstract]   [Full Text] [Related]  

  • 6. Biodegradable polymer luteinising hormone releasing hormone analogue for prostatic cancer: use of a new peptide delivery system.
    Williams G; Kerle D; Griffin S; Dunlop H; Bloom SR
    Br Med J (Clin Res Ed); 1984 Dec; 289(6458):1580-1. PubMed ID: 6239674
    [No Abstract]   [Full Text] [Related]  

  • 7. Oestrogen pre-treatment abolishes luteinising hormone-releasing hormone testosterone stimulation.
    Kreis W; Ahmann FR; Jordan VC; de Haan H; Scott M
    Br J Urol; 1988 Oct; 62(4):352-4. PubMed ID: 2973364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormonal cytoreduction and radiotherapy for carcinoma of the prostate.
    Shearer RJ; Davies JH; Gelister JS; Dearnaley DP
    Br J Urol; 1992 May; 69(5):521-4. PubMed ID: 1535824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombin III concentration, thrombosis, and treatment with luteinising hormone releasing hormone agonist in prostatic carcinoma.
    Varenhorst E; Svensson M; Hjertberg H; Malmqvist E
    Br Med J (Clin Res Ed); 1986 Apr; 292(6525):935-6. PubMed ID: 2938662
    [No Abstract]   [Full Text] [Related]  

  • 10. Review of the endocrine actions of luteinising hormone-releasing hormone analogues in premenopausal women with breast cancer.
    Nicholson RI; Walker KJ; Walker RF; Read GF; Turkes A; Robertson JF; Blamey RW
    Horm Res; 1989; 32 Suppl 1():198-201. PubMed ID: 2533149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter trial comparing the luteinizing hormone releasing hormone analog Zoladex, with Zoladex plus flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group.
    Lunglmayr G
    Eur Urol; 1990; 18 Suppl 3():28-9. PubMed ID: 2151273
    [No Abstract]   [Full Text] [Related]  

  • 12. Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions.
    Chrisp P; Goa KL
    Drugs; 1991 Feb; 41(2):254-88. PubMed ID: 1709853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of previous endocrine therapy on responses to a single dose of an LHRH analogue.
    Allen JM; Williams G; O'Shea JP; Smith C; Yeo T; Kerle D; Bloom SR
    Urol Res; 1984; 12(5):249-51. PubMed ID: 6240150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of cancer of the prostate. Role of gonadorelin analogs].
    Steg A
    Presse Med; 1989 May; 18(20):1007-9. PubMed ID: 2524792
    [No Abstract]   [Full Text] [Related]  

  • 15. The short-term use of luteinising hormone-releasing hormone analogues in uterine fibroids.
    Van der Spuy ZM; Fieggan AG; Wood MJ; Pienaar CA
    Horm Res; 1989; 32 Suppl 1():137-40. PubMed ID: 2533144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of advanced prostatic carcinoma with a slow release depot LHRH analogue (Zoladex depot).
    Lukkarinen O; Kontturi M
    Scand J Urol Nephrol Suppl; 1988; 110():109-12. PubMed ID: 2973121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Chemical castration using a depot LHRH-agonist as a palliative therapy concept in prostatic carcinoma--clinical, endocrinological and experimental studies].
    Kuber W; Treu T; Kratzik C; Girsch E; Zeillinger R; Spona J
    Wien Klin Wochenschr; 1990 Nov; 102(21):640-7. PubMed ID: 2148044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [LHRH analogs--new possibilities in the treatment of prostatic cancer].
    Baranowska B
    Pol Tyg Lek; 1984 Jul 16-23; 39(29-30):1009-12. PubMed ID: 6239145
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug therapy of prostatic cancer.
    Huben RP; Perrapato SD
    Drugs Aging; 1991; 1(5):353-63. PubMed ID: 1838950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of advanced carcinoma of the prostate with a depot luteinizing hormone-releasing hormone analogue (ICI-118630).
    Van Cangh PJ; Opsomer RJ
    J Urol; 1987 Jan; 137(1):61-4. PubMed ID: 2948026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.